Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.

Bradley A. McGregor(Harvard University), Guru Sonpavde(AdventHealth Orlando), Praful Ravi(Dana-Farber Cancer Institute), Lucia Kwak(Harvard University), Arvind Ravi(Broad Institute), Jacob E. Berchuck(Dana-Farber Cancer Institute), Wenxin Xu(Dana-Farber Cancer Institute), Joaquim Bellmunt(Dana-Farber Cancer Institute), Martha Tuff(Dana-Farber Cancer Institute), Charlene Mantia(Dana-Farber Cancer Institute), Xīn Gào(Qingdao University), Rajitha Sunkara(Beverly Hospital)
Journal of Clinical Oncology
February 16, 2022
10.1200/jco.2022.40.6_suppl.tps588
Cited by 7

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
|Cell|2017|2.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k